The US$ 64 billion global clinical research industry is witnessing a transition since lifescience companies are turning toward emerging markets in Asia, Latin America and Eastern Europe, to pursue clinical research. Increasing costs, declining productivity and rising drug development timelines, combined with the strategic advantages offered by these emerging markets, is directing research-driven pharmaceutical and biotechnology companies to conduct clinical research beyond established markets.
.jpg)
No comments:
Post a Comment